COMMUNIQUÉS West-GlobeNewswire

-
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
16/09/2025 -
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
16/09/2025 -
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
16/09/2025 -
Conavi Medical Submits Next Generation Novasight Hybrid Intravascular Imaging System to US FDA for 510(k) Clearance
16/09/2025 -
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
16/09/2025 -
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
16/09/2025 -
Hop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon Ducks
16/09/2025 -
Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology
16/09/2025 -
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/09/2025 -
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
16/09/2025 -
Verano Broadens Florida Retail Footprint to 82 Dispensaries with the Opening of MÜV Crystal River
16/09/2025 -
Focal One® HIFU Receives Prestigious Innovation Award
16/09/2025 -
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
16/09/2025 -
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
16/09/2025 -
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
16/09/2025 -
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
16/09/2025 -
Spectral Medical Announces Publication of EDEN Observational Study
16/09/2025 -
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
16/09/2025 -
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
16/09/2025
Pages